iISSCA 2018 Korea Fellowship

 

 

 

 

 

The International Society for Stem Cell Application (ISSCA) has scheduled the first Cell Therapy and Tissue Engineering Fellowship in the upcoming year for March 5, 2018. The 6-day immersive program will be held in Seoul, Korea.

ISSCA 2018 Korea Fellowship

MIAMI, Nov. 9, 2017—The International Society for Stem Cell Application (ISSCA), a global leader in regenerative medicine education, research, and certification, will hold the first Cell Therapy and Tissue Engineering fellowship for the upcoming year on March 5, 2018, in Seoul, Korea.

Following up on the success of the organization’s series of fellowships in 2017, ISSCA decided to continue to offer the opportunity to graduate and post-doctoral students. Participants will engage with world-class stem cell and regenerative medicine experts in an immersive, hands-on experience focused on stem cell characterization and laboratory applications including cell culture, plating, trypsinization, harvesting, and cryopreservation. Fellowship attendants also gain an understanding of control tests including cell count, viability, flow cytometry, endotoxin, mycoplasma, and sterility.

“The very nature of stem cell therapy and tissue engineering necessitates practical, immersive, and skillfully monitored participation for students training in the application of stem cells,” says Benito Novas, ISSCA Public Relations Director and founder of Global Stem Cells Group. “The opportunity to actively engage while learning theoretical and analytical methods from mentors working to create new medical technologies and laboratory applications in one of the most rapidly growing areas of biomedical engineering is highly advantageous.

“Bio-medical scientists encounter many challenges before tissue engineering therapies reach clinical use and widespread application,” Novas says. “Cell therapy and tissue engineering offer vast potential for a career as a practitioner or researcher in which today’s students can be tomorrow’s pioneers in improving the efficacy of medical treatments and advancing the healthcare industry.”

And since so many tissues and organs are excellent candidates for engineering new treatments and cures for diseases, including blood vessel, bone, cartilage, liver, pancreas, peripheral nerve, and skin cells, the future of regenerative medicine has the potential to revolutionize disease remediation and tissue repair

The ISSCA Fellowship in Cell Therapy and Tissue Engineering is a 6-day workshop that offers a certificate of completion issued by ISSCA and Westminster International University in Seoul.  Students who complete the fellowship become members of the ISSCA’s international network of regenerative medical professionals and standard setters, with access to events, resources, training, and support moving forward.

ISSCA is the only organization that provides a complete Cell Therapy and Engineering Tissue Fellowship focused on regenerative medicine. It is also the only fellowship of its kind supported by Korean Universities.

To learn more about the ISSCA fellowship and to reserve a spot at the March 8, 2018 program in Korea, visit http://stemcellsacademy.com, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

###

.

ISSCA 2018 Korea Fellowship

regenerative-medicine-certification-training

 

 

 

 

 

 

 

The International Association for Stem Cell Application (ISSCA) will be conducting a regenerative medicine certification course for physicians in Buenos Aires Nov. 26-27, 2017. The two-day intensive training course teaches trainees extraction, isolation, and application of PRP, adipose, and bone marrow stem cells.

 

regenerative medicine certification training

MIAMI, Nov. 9, 2017— The International Society for Stem Cell Application (ISSCA), a global leader in regenerative medicine training, has announced plans to conduct regenerative medicine certification training for physicians in Buenos Aires, Argentina November 26 – 27, 2017.

The ISSCA training course, available to qualified physicians interested in adding regenerative medicine to their practice procedures, provides hands-on, practical instruction under the guidance of trained medical experts in a highly visual, interactive, and clinical learning environment.

.ISSCA’s medical professionals teach reintegration and procedural techniques on live patients using different protocols for isolating stem cells. Trainees will participate in different medical cases under the supervision of trained specialists.

This hands-on stem cell training course provides each participant with a live demonstration of the extraction, isolation, and application of PRP, adipose, and bone marrow stem cells. Techniques and materials used in the course, along with high-resolution, step-by-step procedure videos are provided for the participating physician’s future use and reference.

Led by ISSCA’s established team of skilled practitioners, this course is designed specifically to provide personalized instruction. Seats for each course are limited to 8-10 trainees, not only to suit each participant’s individual training needs but also to allow for professional networking.

Participants who complete the training will receive certification that documents their participation in and completion of the training, their and their knowledge and skills in the field of regenerative medicine. Certification candidates are required to provide proof of prior medical training and experience, and successfully complete a written as well as an oral/practical exam. Certification confirms a physician’s expertise in regenerative medicine.

​Certification procedures and requirements are key to the integrity of regenerative medicine. They furnish a reputable credential that is essential not only for patients to see, but also to a physician’s practice.

The Buenos Aires certification training course will mark the 11th event ISSCA has sponsored and hosted thus far in 2017. The organization is working to position itself as a reference point for regenerative medical practitioners worldwide. With a presence in more than 25 countries, physicians interested in certification can check for an ISSCA training course near them by visiting the https://www.stemcelltraining.net/ website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.                                                                                                               ###
Regenerative medicine certification training

a4m-25th-annual-world-congress

(Pictured at left) Integrated Stem Cell Work Station, a new multi-functional bio-work station from AdiMarket,

 

 

 

 

 

Adimarket, a division of Global Stem Cells Group announces its sponsorship of the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress in Las Vegas Dec. 14-16. GSCG plans to launch two new products for stem cell and regenerative medicine practitioners at the event.

a4m-25th-annual-world-congress

 

MIAMI, Nov. 9, 2017—Adimarket, a division of Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, announces its sponsorship of the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress in Las Vegas, Dec. 14 – 16, 2017. This year marks a quarter-century in A4M’s mission to build awareness and deliver innovative, cutting-edge scientific education in the field of anti-aging medicine.

A4M focuses on longevity and prolonging the lifespan of people worldwide. Global Stem Cells Group shares A4M’s commitment to promoting anti-aging medicine, having organized five regenerative medicine symposiums and other medical conferences highlighting anti-aging research and therapies in 2017.

 

a4m 25th annual world congress

Global Stem Cells Group will leverage the large gathering of regenerative medicine and healthcare professionals at theInternational Congress to launch its newest cutting-edge online regenerative medicine training course in collaboration with StemCell Training, Inc.

The new virtual regenerative medicine training course is designed to instruct qualified physicians in the theoretical and practical protocols necessary to effectively and expertly administer regenerative medicine procedures to their patients. Training includes instructions for harvesting and isolating stem cells. The online training program positions physicians to provide stem cell procedures in their existing practice or open a stem cell center practice and join ISSCA’s international network of stem cell specialists.

GSCG will also launch two new products at the A4M conference:

  1. STEMPIA, a new adipose-derived stem cell kit. The kit provides two specially designed tubes to isolate and concentrate adipose tissue-derived stromal vascular fraction (SVF). STEMPIA offers an easier, more effective, and shorter process for SVF isolation while maintaining high viability rates. STEMPIA uses fewer consumables and tools compared to manual SVF isolation processes, saving both costs and time in the SVF isolation process.
  2. The latest Integrated Stem Cell Work Station from AdiMarket, a multi-functional bio-work station that allows physicians to perform stem cell protocols and procedures within an enclosed controlled culture environment. The Integrated Stem Cell Work Station is equipped with a built-in centrifuge, shaking incubator, laminar flow hood and other features to ensure a clean environment for stem cell isolation and handling. It can also be customized to accommodate insertion of supplementary device(s) in work station.

The American Academy of Anti-Aging Medicine (A4M) 25th Annual World Congress will be hosted at the Venetian and Palazzo Resort, a hotel and casino resort located on the Las Vegas Strip.

To learn more about the A4M World Congress, visit the event website. For more information about Global Stem Cells Group, visit the GSCG website, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

###

A4M 25th Annual World Congress

Stem Cell training Lima Peru

The International Association for Stem Cell Application (ISSCA) has announced plans to host three regenerative medicine symposiums in Istanbul, Turkey, Buenos Aires, Argentina, and Seoul, Korea in 2018. The Seoul symposium will be part of, the 6th Annual International Conference of ISSCA, “Progress and Perspectives,” which will be held in Seoul in November 2018.

 

regenerative-medicine-symposiums-2018 ISSCA

MIAMI, Nov. 9, 2017—The International Association for Stem Cell Application (ISSCA) has announced plans to host three regenerative medicine symposiums in the upcoming year:

  • Istanbul, Turkey, April 2018
  • Buenos Aires, Argentina, August 2018
  • Seoul, Korea, November 2018

The symposium series will culminate in the 6th Annual International Conference of ISSCA, Progress and Perspectives, in Seoul, Korea in November 2018.

The three international symposiums are part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research. Each event will host a group of renowned international speakers in the field of stem cell and regenerative medicine, who will offer a day of rigorous scientific discourse aimed at physicians.

Each ISSCA symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells. Business opportunities, challenges, and potential strategies for overcoming these challenges will also be addressed.

The central theme of each international symposium is as follows:

•  Istanbul: Advances in Cell Therapies
•  Buenos Aires:  Next Generation Medicine: Adult Stem Cells
•  Seoul: This seminar will be part of the 6th Annual International Conference of ISSCA, “Progress and Perspectives”

Symposium dates and details will be available shortly. To learn more about the ISSCA symposiums and 6th Annual International Conference of ISSCA, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.###

Regenerative medicine symposiums 2018 ISSCA

Cell Processing urn-key solution

Cell processing turn-key solution

Global Stem Cells Group and its affiliate AdiMarket announce the new Turn-Key Solution, a one-stop solution that provides high-quality stem cell processing equipment and kits and the expert help needed to set up a stem cell lab in-clinic or in-hospital.


MIAMI, Nov. 9, 2017—Global Stem Cells Group (GSCG) and its affiliate AdiMarket now offer a new, turn-key solution for stem cell processing. The AdiMarket Turn-Key Solution is a one-stop solution that provides high-quality equipment and kits required for stem cell processing and the expert help needed to set up a stem cell processing lab in-clinic or in-hospital. It can also be designed for complex protocols such as cryopreservation, culturing, and expansion of adult stem cells derived from adipose tissue and bone marrow.

Cell processing turn-key solution

GSCG and AdiMarket provide everything needed to bring this ready-to-go cell processing expansion lab to scientists andinstitutions worldwide. Physician training courses in the field of regenerative medicine are also available to qualified physicians. These expert training courses provide hands-on, practical instruction under the guidance of trained medical experts in a highly visual, interactive, and clinical learning environment.

The AdiMarket Turn-Key Solution is a complete solution for installing highly customized, in-clinic or in-hospital turn-key laboratories to meet each facility’s individual needs.

“A well-planned, organized, and properly equipped laboratory supports critical research and favorable procedure outcomes by increasing efficiency and reducing lost time and wasted resources,” says Benito Novas, Global Stem Cells Group founder and CEO.  This is vital to continuing to the discovery and implementation of new methods for treating patients.”

Admarket is GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering all the tools and products practitioners need to facilitate in-office, in-clinic, or in-hospital stem cell procedures. From planning to building the lab, to training and consultation, Turn-Key Solution users are equipped in every way possible to walk in and begin using their fully-outfitted biotechnology lab.

To learn more about Global Stem Cells Group and the AdiMarket Turn-Key Solution, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

###

Cell Processing urn-key solution

 

 

 

Click on photo (at left) to enlarge
Photo: iPS cells feature – reprogrammed stem cells: Credit: Moscow Institute of Physics and Technology

Russian researchers have concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells.

Stem cells are specialized, undifferentiated cells that can divide and have the remarkable potential to develop into many different cell types in the body during early life and growth. They serve as a sort of internal repair system in many tissues, dividing essentially without limit to replenish other cells. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another more specialized cell type, such as a muscle cell, a red blood cell, or a brain cell. Scientists

distinguish several types of stem cells—pluripotent stem cells can potentially produce any cell in the body. No pluripotent stem cells exist in an adult body, rather they are found naturally in
early embryos.

There are two ways to harvest pluripotent stem cells. The first is to extract them from the excess embryos produced during invitro fertilization procedures, although this practice is still ethically and technically controversial because it does destroy an embryo that could have been implanted. For this reason, researchers came up with the second way to get pluripotent stem cells— reprogramming adult cells.

Reprogramming, the process of “turning on” genes that are active in a stem cell and “turning off” genes that are responsible for cell specialization was pioneered by Shinya Yamanaka, who showed that the introduction of four specific proteins essential during early embryonic development could be used to convert adult cells into pluripotent cells. Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon for the discovery that mature stem cells can be reprogrammed to become pluripotent.

reprogram3use

Production of iPS cells:
• Isolate cells from patient; grow in a dish •
Treat cells with “reprogramming”
• Wait a few weeks
• Pluripotent stem cells
• Change culture conditions to stimulate cells to differentiate into a variety of cell types
• blood cells  |   gut cells   |  cardio muscle cells
Credit: Moscow Institute of Physics and Technology

Thanks to their unique regenerative abilities, stem cells offer potential for treating any disease. For example, there have been cases of transplanting retinal pigment epithelium and spine cells from stem cells. Another experiment showed that stem cells were able to regenerate teeth in mice. Reprogramming holds great potential for new medical applications,  since reprogrammed pluripotent stem cells (or induced pluripotent stem cells) can be made from a patient’s own cells instead of using pluripotent cells from embryos.

However, the extent of the similarity between induced pluripotent stem cells and human embryonic stem cells remains unclear. Recent studies highlighted significant differences between these two types of stem cells, although only a limited number of cell lines of different origins were analyzed.

Researchers compared induced pluripotent stem cell (iPSC) lines reprogrammed from adult cell types that were previously differentiated from embryonic stem cells. All these cells were isogenic, meaning they all had the same gene set.

Scientists analyzed the transcriptome – the set of all products encoded, synthesized and used in a cell. Moreover, they elicited methylated DNA areas, because methylation plays a critical role in cell specialization. Comprehensive studies of changes in the gene activity regulation mechanism showed similarities between reprogrammed and embryonic stem cells. In addition, researchers produced a list of the activity of 275 key genes that can present reprogramming results.

Researchers studied three types of adult cells – fibroblasts, retinal pigment epithelium and neural cells, all of which consist of the same gene set; but a chemical modification (e.g. methylation) combined with other changes determines which part of DNA will be used for product synthesis.

Scientists concluded that the type of adult cells that were reprogrammed and the process of reprogramming did not leave any marks. Differences between cells that did occur were thought to be the result of random factors.

“We defined the best induced pluripotent stem cells line concept,” says Dmitry Ischenko, MIPT Ph.D. and Institute of Physical Chemical Medicine researcher.

The minimum number of iPSC clones that would be enough for at least one to be similar to embryonic pluripotent cells with 95 percent confidence is five.”

programmed stem cellsClearly, no one is going to convert embryonic stem cells into neurons and reprogram them into induced stem cells. Such a process would be too time-consuming and expensive. This experiment simulated the reprogramming of a patient’s adult cells into induced pluripotent stem cells for further medical use, and even though the reprogramming paper, published in the journal Cell Cycle, does not currently propose a method of organ growth in vitro, it is an important step in the right direction. Both induced pluripotent cells and embryonic stem cells can help researchers understand how specialized cells develop from pluripotent cells. In the future, they may also provide an unlimited supply of replacement cells and tissues that can benefit many patients with diseases that are currently untreatable.

The study, titled, “An integrative analysis of reprogramming in human isogenic system identified a clone selection criterion,” concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells, involved researchers from the Vavilov Institute of General Genetics, Research Institute of Physical Chemical Medicine, and the Moscow Institute of Physics and Technology (MIPT).

###

human stem cells

Scientists from the U.K. and Sweden have discovered a new method of creating human stem cells that could solve the problem of meeting large-scale production needs, allowing researchers to fully realize the potential of stem cells for understanding and treating disease.

Human pluripotent stem cells are undifferentiated cells that have the unique potential to develop into all the different types of
cells in the body. With applications in disease modeling, drug screening, regenerative medicine and tissue engineering, there is already an enormous demand for these cells, and that demand will continue grow as their use in clinical settings and the pharmaceutical industry increases.

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue). Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham Read more at: http://phys.org/news/2016-07-breakthrough-scaling-life-changing-stem-cell_line

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue).
Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham.

However, production of stem cells at the scale required for optimal application in modern research and healthcare has not beenfeasible because available culture methods are either too expensive, or reliant on substances that would not be safe for clinical use in humans.

The research results, published in Nature Communications in July, describe how the scientific team from The University of Nottingham’s Wolfson Centre for Stem Cells, Tissue Engineering and Modelling at Uppsala University in Sweden and GE Healthcare also in Sweden have identified and improved human stem cell culture methods that could lead to quicker and cheaper large scale industrial production of human pluripotent stem cells.

By using a protein derived from human blood called Inter-alpha inhibitor, the team has grown human pluripotent stem cells in a minimal medium without the need for costly and time-consuming biological substrates. Inter-alpha inhibitor is found in human blood at high concentrations, and is currently a by-product of standard drug purification schemes.

The human serum-derived protein can make stem cells attach to unmodified tissue culture plastic, eliminating the need for coating in defined human pluripotent stem cell culture, and improving survival capabilities of the stem cells in harsh conditions.

It is the first stem cell culture method that does not require a pre-treated biological substrate for attachment, and therefore, is more cost and time efficient, paving the way for easier and cheaper large-scale production.

Existing methods are time consuming and make developing human stem cell cultures prohibitively costly. This new method has the potential to save time and money in large-scale and high-throughput cultures, and be highly valuable for both basic research and commercial applications.

The work began at Uppsala University, and the study’s first author, Sara Pijuan-Galitó PhD., is continuing her work as a Swedish Research Council Research Fellow at Nottingham.

Researchers now intend to combine Inter-alpha inhibitor protein with an innovative hydrogel technology to improve on current methods for controlling cell differentiation, and also apply it to disease modelling. The discovery, according to the findings, will help facilitate research into many diseases although their focus is currently on understanding rare conditions like Multiple Osteochondroma) at the cellular level. The aim is to replicate the 3 dimensional environment that cells experience within the body so that lab-bench biology is more accurate in modelling diseases.

Pijuan-Galitó has been awarded the Sir Henry Wellcome Postdoctoral Fellowship at Nottingham University for her work on the research, which will enable her to combine Inter-alpha inhibitor with improved synthetic polymers in collaboration with fellow regenerative medicine pioneers Professor Morgan Alexander and Professor Chris Denning. The team plans to further improve on current human stem cell culture by designing an economical and safe method that can be easily translated to large-scale production and can deliver billions of stem cells necessary move cellular therapeutics forward in patient settings.

The study, titled “Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture,” was published in Nature Communications in July, 2016.

###

liver stem cell research

Researchers from the Medical University of South Carolina (MUSC) and the University of Pennsylvania have discovered a new methodology for purifying liver cells generated from induced pluripotent stem cells (iPSCs) that could facilitate progress toward an important clinical goal: treating patients with disease-causing liver mutations by transplanting unmutated liver cells derived from their own stem cells.

This new technique follows previous attempts to generate liver-like cells from stem cells, which have yielded heterogeneous cell populations with little similarity to diseased livers in patients.

liver cell

Image: induced pluripotent stem cells expressing a characteristic cell surface protein called SSEA4 (green).
Credit: Image courtesy of Stephen A. Duncan, Ph.D., at the Medical University of South Carolina

The National Heart, Lung, and Blood Institute (NHLBI)’s Next Generation Genetic Association Studies Program (Next Gen) was created to bank stem cell lines sourced from patients in genome-wide association studies (GWAS). The goal of the Next Gen Lipid Conditions sub-section – a collaborative effort between Stephen A. Duncan, Ph.D., chair of regenerative medicine at MUSC and Daniel J. Rader, M.D. and Edward E. Morrisey, Ph.D., both at the University of Pennsylvania – is to help determine the genetic sources of heart, lung or blood conditions that also include the liver.

The GWAS studies map the genomes in hundreds of people as a way to look for genetic mutation patterns that differ from the genomes of healthy individuals. As GWAS study map more genomes, they become more likely to find the correct genetic mutations that cause a disease. Once a panel of suspected mutations is built, stem cells from these individuals can be manipulated in culture dishes to differentiate into any of the body’s cells. The cells can be screened to learn more about the mutations and to test panels of drugs that might ultimately help treat patients harboring a disease.

Problems arise during the cell manipulation process. For example, iPSCs persistently refuse to mature uniformly into liver-like cells when fed growth factors. Traditionally, antibodies have been used to recognize features of maturity on the surfaces of cells and purify cells that are similar, an approach that has been crucial to stem cell research. But available antibodies that recognize mature liver cells are scanty and tend to recognize many different kinds of cells. The many types of cells in mixed populations have diverse characteristics that can obscure underlying disease-causing genetic variations, which tend to be subtle.

“Without having a pure population of liver cells, it was incredibly difficult to pick up these relatively subtle differences caused by the mutations, but these differences are important in the life of an individual,” Duncan says.

Instead of relying on antibodies, Duncan and his team embraced a new technology called chemo proteomic cell surface capture (CSC) technology. CSC technology allowed the researchers to map the most highly produced proteins on the surface of liver cells during the final stages of differentiation of stem cells into liver cells. The most abundant protein was targeted with an antibody labeled with a fluorescent marker and used to sort the mature liver cells from the rest.

The procedure was highly successful: The team had a population of highly pure, homogeneous and mature liver-like cells. Labeled cells had far more similar traits of mature hepatocytes than unlabeled cells. Pluripotent stem cells that had not differentiated were excluded from the group of labeled cells.

“That’s important,” says Duncan. “If you’re wanting to transplant cells into somebody that has liver disease, you really don’t want to be transplanting pluripotent cells because pluripotent cells form tumors called teratocarcinomas.”

Duncan cautioned that transplantation of iPSC-derived liver cells is not yet ready for translation to the clinic, but the technology for sorting homogeneous liver cells can be used now to successfully and accurately model and study disease in the cell culture dish.

“We think that the ability to generate pure populations will get rid of the variability, and therefore really help us combine with GWAS studies to identify allelic variations that are causative of a disease, at least in the liver,” he says.

Researchers at the University of Minnesota (Minneapolis) and the Medical College of Wisconsin (Milwaukee) contributed to the study, published August 25, in Stem Cell Reports.

###

stem cell training certification

MIAMI, Sept. 13, 2016-Global Stem Cells Group announced plans to hold a stem cell training certification course Oct. 1 -2, 2016 following the 3rd annual Global Stem Cells Group International Symposium on Stem Cells and Regenerative Medicine in Buenos Aires. The symposium will take place Sept. 28, 2016.

The two-day, hands-on training course covers the latest technology and procedures in SVF and bone marrow stem cell techniques. Practitioners learn skills that can be used to treat patients in their practices, and for career advancement. The SVF and bone marrow aspiration course was developed for physicians and high-level practitioners to learn techniques in harvesting and rein

stem cell training certification

Joseph Purita, MD

tegrating stem cells derived from adipose tissue and bone marrow. The objective of the training teach effective, in-office regenerative medicine techniques.

stem cell training certification

Silvina Pastrana, M.D.

The course will be taught by GSCG Advisory Board members Joseph Purita, M.D. and Silvina Pastrana, M.D.

The stem cell training certification course will be held at the Global Subsidiary Stem Cell Center Network in Puerto Madero Buenos Aires immediately following the 3rd annual International Symposium on Stem Cells and Regenerative Medicine.

Since 2014, Global Stem Cells Group has joined forces with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the anti-aging aesthetics industry and help improve the quality of life for patients suffering from some chronic conditions.

To learn more about the 3rd Annual International Symposium on Stem Cells and Regenerative Medicine, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
stem cell training certification
About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

To view this press release live online, click here

###

Panama Congress

MIAMI, Sept. 9, 2016—Global Stem Cells Group will attend the Colombian Association of  Sports Medicine’s First Latin American Congress on Sports Medicine, Injuries, Treatment and Rehabilitation in Panama City, Panama Sept. 22 – 24, 2016. The Panama Congress will focus on a variety of Sports Medicine specialties presented in an academic activity framework.

The congress will host a diverse range of esteemed guests, including physicians, athletes, athletic coaches, physical therapists, medical exercise physiologists, orthopedists, physical medicine and rehabilitation (PM&R) physicians (physiatrists), Paralympics athletes, endocrinologists, diabetologists, orthopedic surgeons, internists, physical educators, pain specialists, nutrition and dietetic specialists, psychologists, neuro surgeons and neuro rehabilitation specialists.

The event, to be hosted at the Hotel Riu Plaza in the heart of Panama City’s financial district, will provide a dynamic atmosphere showcasing local, national, international and Latin American ambience.

To learn more about the First Latin American Congress on Sports Medicine, visit the event website.To learn more about Global Stem Cells Group, visit the GSCG website, email bnovas(at)stemellsgroup.com, or call 305-560-5337.

Panama Congress

About Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

To review this press release live online, click here

###